Frontiers in Oncology | Hematologic Malignancies

Original Research

Published on 16 Jan 2023

High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification

in Hematologic Malignancies

Xiaoyu Wang
Dan Liu
Erling Chen
Li Wang
Na Zhao
Li Zhou
Juan Tong
Lei Xue
Lei Zhang
Liangquan Geng

Frontiers in Oncology

doi 10.3389/fonc.2022.1070588

2,450 views
2 citations

Review

Published on 13 Jan 2023

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity

in Hematologic Malignancies

Aisling Barrett
Graham P. Collins

Frontiers in Oncology

doi 10.3389/fonc.2022.1017787

10,141 views
5 citations

Case Report

Published on 12 Jan 2023

Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib

in Hematologic Malignancies

Anna E. Johnson
Athul Raj Raju
Aasems Jacob
Gerhard C. Hildebrandt

Frontiers in Oncology

doi 10.3389/fonc.2022.1100577

3,819 views
6 citations

Original Research

Published on 12 Jan 2023

Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma

in Hematologic Malignancies

Bingxin Zhang
Tianyu Zhang
Ziwei Zheng
Zhili Lin
Quanqiang Wang
Dong Zheng
Zixing Chen
Yongyong Ma

Frontiers in Oncology

doi 10.3389/fonc.2022.1020566

4,678 views
9 citations

Systematic Review

Published on 12 Jan 2023

Harnessing the immune system in the treatment of cutaneous T cell lymphomas

in Hematologic Malignancies

Christopher J. Fay
Katherine C. Awh
Nicole R. LeBoeuf
Cecilia A. Larocca

Frontiers in Oncology

doi 10.3389/fonc.2022.1071171

4,297 views
1 citation

Case Report

Published on 10 Jan 2023

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia

in Hematologic Malignancies

Fabio Giglio
Edoardo Campodonico
Francesca Lorentino
Maddalena Noviello
Elisabetta Xue
Raffaella Greco
Lorenzo Lazzari
Alessandro Bruno
Maria Teresa Lupo Stanghellini
Matteo Giovanni Carrabba

Frontiers in Oncology

doi 10.3389/fonc.2022.1100105

3,128 views

Original Research

Published on 09 Jan 2023

Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma

in Hematologic Malignancies

Giulia Mura
Elif Karaca Atabay
Matteo Menotti
Cinzia Martinengo
Chiara Ambrogio
Gloria Giacomello
Maddalena Arigoni
Martina Olivero
Raffaele A. Calogero
Roberto Chiarle

Frontiers in Oncology

doi 10.3389/fonc.2022.1085672

4,491 views
3 citations

Case Report

Published on 09 Jan 2023

Case report: Identification of a novel HNRNPC::RARG fusion in acute promyelocytic leukemia lacking RARA rearrangement

in Hematologic Malignancies

Wenjing Ding
Guangyang Weng
Zheng Wang
Yusha Guo
Man Wang
Hongjie Shen
Suning Chen
Xin Du
Lijun Wen

Frontiers in Oncology

doi 10.3389/fonc.2022.1028651

2,804 views
9 citations

Original Research

Published on 06 Jan 2023

Age-period-cohort analysis of gender differential trends in incidence and mortality of non-Hodgkin lymphoma in China, 1990-2019

in Hematologic Malignancies

Yuanyuan Yao
Hui Liu
Fei Zhao
Shengli Zhang
Xingrong Liu

Frontiers in Oncology

doi 10.3389/fonc.2022.1056030

2,570 views
5 citations

Review

Published on 05 Jan 2023

Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?

in Hematologic Malignancies

Kotaro Miyao
Hirofumi Yokota
R. Leo Sakemura

Frontiers in Oncology

doi 10.3389/fonc.2022.1082235

5,282 views
5 citations

Opinion

Published on 04 Jan 2023

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma

in Hematologic Malignancies

Colin Thomas
Sameep Thapa
Connor McLaughlin
Molly Halloran
Pierluigi Porcu

Frontiers in Oncology

doi 10.3389/fonc.2022.1098375

11,683 views
2 citations

Original Research

Published on 04 Jan 2023

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

in Hematologic Malignancies

Sabine Felser
Julia Rogahn
Philipp le Coutre
Haifa Kathrin Al-Ali
Susann Schulze
Lars-Olof Muegge
Julia Gruen
Jan Geissler
Veronika Kraze-Kliebhahn
Christian Junghanss

Frontiers in Oncology

doi 10.3389/fonc.2022.1056786

1,893 views
5 citations

Case Report

Published on 04 Jan 2023

Case report: Rosai-Dorfman disease with rare extranodal lesions in the pelvis, heart, liver and skin

in Hematologic Malignancies

Misaki Yoshida
Takeshi Zoshima
Satoshi Hara
Yoshinori Takahashi
Ryo Nishioka
Kiyoaki Ito
Ichiro Mizuhima
Dai Inoue
Satoko Nakada
Mitsuhiro Kawano

Frontiers in Oncology

doi 10.3389/fonc.2022.1083500

1,993 views
3 citations

Original Research

Published on 04 Jan 2023

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation

in Hematologic Malignancies

Juan Chen
Li Liu
Runzhi Ma
Aiming Pang
Donglin Yang
Xin Chen
Jialin Wei
Yi He
Rongli Zhang
Weihua Zhai

Frontiers in Oncology

doi 10.3389/fonc.2022.1025885

2,877 views
7 citations

Review

Published on 04 Jan 2023

Role of Notch2 pathway in mature B cell malignancies

in Hematologic Malignancies

Nicolò Mesini
Stefania Fiorcari
Claudio Giacinto Atene
Rossana Maffei
Leonardo Potenza
Mario Luppi
Roberto Marasca

Frontiers in Oncology

doi 10.3389/fonc.2022.1073672

4,839 views
8 citations

Systematic Review

Published on 29 Dec 2022

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis

in Hematologic Malignancies

Lili Li
Luqin Wang
Qinhua Liu
Zhonghui Wu
Yulong Zhang
Ruixiang Xia

Frontiers in Oncology

doi 10.3389/fonc.2022.954345

3,462 views
7 citations